← ANALYST RATINGS · TIPRANKS

Embecta Corporation (EMBC): analyst forecast and price target

$6.27 −2.79% close 16.10.26 · market cap $365M · Healthcare · Medical - Instruments & Supplies IWM 0.01%
Price targets and ratings of

Analyst consensus

Moderate Sell

0 Buy1 Hold1 Sell

Ratings of 2 analysts in the last 3 months

12-month forecast

—— upside

Based on 2 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $6.27.

$5.00$10.00Jan 26AprJulOctJan 27AprJulOct
Highest target — Average target — Lowest target —
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% BTIG — Hold — Reiterated 09.10.26on TipRanks Oct 12 09:45 −1.7%next day +5.4% · 5 days +12.3%
Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% Bank of America Securities — Sell — Reiterated 10.08.26on TipRanks 09:55 +12.9%next day −1.9% · 5 days +2.9%
Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% BTIG — Hold — Reiterated 15.06.26on TipRanks Jun 17 08:06 −0.8%next day −0.7% · 5 days +2.6%
Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% Mizuho Securities $12.00 → $5.00−58.3% Hold −20.3% Reiterated 06.05.26on TipRanks May 9 11:05 −10.1%next day +1.4% · 5 days −13.5%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Embecta Corporation

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%
1 year Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%
2 years Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%

Most profitable

3 months Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%
1 year Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%
2 years Travis Steed★★★★★★★★★★Bank of America Securities · #3596
Hits 53%196 of 370 Average return +3.0%

Recommendation trend

0246311Oct 2521Nov1Dec1Jan 262Feb3Mar51Apr331May241Jun31Jul11Aug1Sep11Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy320000
Buy000000
Hold343101
Sell111111

Earnings and sales forecast

Next report: 01.12.26 (Q4 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.29 (from $0.28 to $0.31). Last quarter: $0.56.

Sales

Next quarter’s sales estimate — $267M (from $258M to $270M). Last quarter: $272M.

Best top-analyst consensus in the sector · Healthcare

OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist TherapeuticsStrong Buy
ESTAEstablishment Labs HoldingsStrong Buy
REPLReplimune GroupStrong Buy
About Embecta Corporation
  • CEO: Devdatt Kurdikar
  • Employees: 1,850
  • 300 Kimball Drive, Parsippany, NJ, 07054, US
  • www.embecta.com

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Data from the stock’s TipRanks forecast page, read 217 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗